<DOC>
	<DOC>NCT02600845</DOC>
	<brief_summary>This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management System over a period of 6 months.</brief_summary>
	<brief_title>ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Diagnosis of type 1 or type 2 diabetes for greater than or equal to (&gt;=) 6 months Currently using insulin as a component of the diabetes therapy Allow and be able to provide selfmonitoring of blood glucose (SMBG) data at least 1 month prior to study start SMBG frequency as confirmed by site SMBG data download of participants meter(s): Basal insulin treated participants SMBG &gt;=5 times per week and Multiple dose insulin participants SMBG &gt;=2 times per day Glycosylated hemoglobin (HbA1c) of &gt;=7.5 percentage (per local laboratory obtained less than or equal to [&lt;= 3] months of Baseline) Able to read and write in English language Currently using a Smartphone and have experience with downloading at minimum one application Smartphone compatibility; must be able to download the ACCUCHEK Connect system application accordingly Naive to the ACCUCHEK Connect system Willing to comply with study procedures Treatment with insulin pump therapy Any use of continuous glucose monitoring (CGM) to manage their diabetes during the course of the study Visually impaired Women who are pregnant, lactating or planning to become pregnant during the study period Diagnosed with any clinically significant condition (for example anemia, major organ system disease, infections, psychosis or cognitive impairment) Participant requires chronic steroid in adrenal suppressive doses, other immunomodulatory medication or chemotherapy Participant is the investigator or any subinvestigator, general practitioner, practice staff, pharmacist, research assistant or other staff or relative of those directly involved in the conduct of the study and design of the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>